Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality

Lancet. 2022 Jul 30;400(10349):338-339. doi: 10.1016/S0140-6736(22)01295-8.

Authors

Puja Mehta¹, Boghuma K Titanji²

Affiliations

¹ Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK; Department of Rheumatology, University College London Hospital NHS Trust, London, UK.
² Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: boghuma.kabisen.titanji@emory.edu.

No abstract available

Publication types

Comment

MeSH terms

Artificial Intelligence
Azetidines* / therapeutic use
COVID-19 Drug Treatment*
Humans
Purines
Pyrazoles
Sulfonamides

Substances

Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib